None listed
Conditions
Interventions
Drug : Patietns who were stable for 12 months after DES implantation in spite of high risk of ischemic and bleedig events would be included in this study and randomly assigned 1:1 to the experimental
Sponsors
Yonsei University Health System, Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria (must all met) 1. Patients >19 years old 2. Patients who underwent DES implantation 12 months (±5 months) previously. 3. High risk characteristics (clinical or lesion) for ischemic events (must at least one) High risk patients; clinical criteria (1) Acute coronary syndrome (2) Previous history of cerebrovascular accidents (3) History of peripheral artery intervention (4) Heart failure (left ventricular ejection fraction =40%) (5) Diabetes treated with medication (6) Chronic renal insufficiency including end-stage renal diseases High risk lesions; angiographic or procedural criteria (1) Left main diseases (2) Bifurcation lesions (3) Chronic total occlusion (4) In-stent restenotic lesions (5) Graft lesions (6) Diffuse long lesions requiring total stent length =28 mm (7) Calcified lesions requiring atherectomy (8) Multivessel coronary artery disease with multiple stents (9) Small vessel disease requiring stent diameter of =2.5 mm
Exclusion criteria
Exclusion criteria: 1. Age> 80 years 2. Pregnant women or women with potential childbearing 3. Life expectancy < 1 year 4. Refusal or inability to understand of informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Net clinical adverse event [NACE] | — |
Secondary
| Measure | Time frame |
|---|---|
| Each components of NACE;All-cause or cardiovascular mortality;Major or minor bleeding;Major adverse cardiac event;Major Adverse Cardiac and Cerebrovascular Event | — |
Countries
Korea, Republic of
Contacts
Public ContactSung-Jin Hong
Yonsei University Health System, Severance Hospital
Outcome results
None listed